Study summary · research use only
[Cerebrolysin for acute ischemic stroke]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review examined evidence on benefits and risks of cerebrolysin, a mixture of low-molecular-weight peptides and amino acids derived from pig brain tissue, for human patients with acute ischemic stroke, via a systematic search and analysis of randomised clinical trials comparing cerebrolysin with placebo. Only one trial was selected as meeting quality criteria. No difference in death and adverse events between cerebrolysin and placebo was established. The authors conclude there is insufficient evidence to evaluate the effect of cerebrolysin on survival and dependency in people with acute ischemic stroke.
Abstract
The review discusses existing evidence of benefits and risks of cerebrolysin--a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue with proposed neuroprotective and neurotrophic properties, for acute ischemic stroke. The review presents results of systematic search and analysis of randomised clinical trials comparing cerebrolysin with placebo in patients with acute ischemic stroke. Only one trial was selected as meeting quality criteria. No difference in death and adverse events between cerebrolysin and placebo was established. The authors conclude about insufficiency of evidence to evaluate the effect of cerebrolysin on survival and dependency in people with acute ischemic stroke.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.